|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
BIGH3 was also induced in some RCC cell lines by TGF-beta1 stimulation and this correlated well with PAI-1 up-regulation, suggesting that these enhancements are regulated by a similar mechanism in these tumors.
|
18357369 |
2008 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
TGFBI methylation was observed in 23 out of 38 (60.5%) cases of ovarian cancer, in no normal ovarian tissues (0 of 38, P=0.001), and in 5 out of 18 (27.8%) borderline tumors (P=0.044).
|
20421128 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TGFBI, a secreted protein that is induced by transforming growth factor-β in various human cell types, has been shown to be associated with tumorigenesis in various types of tumors.
|
21701776 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Transforming growth factor β‑induced (TGFBI) has been implicated as a tumor suppressor, which enhances gemcitabine chemosensitivity in lung cancer cells.
|
26503734 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A good correlation was observed between promoter hypermethylation and lost expression of Betaig-h3 gene, which was supported by the data that demethylation of promoter by 5-aza-2'-deoxycytidine reactivated Betaig-h3 and restored its expression in Betaig-h3-silenced tumor cell lines.
|
16651406 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A significant association was found between the presence of TGFBI expression with tumor category T3-4 (P<0.0001), Fuhrman grades III and IV (P<0.0001), tumor size>4cm (P<0.0001), presence of tumor necrosis (P<0.0001), nodal involvement (n = 0.009), metastasis (P = 0.012), SSIGN score≥5 (P<0.0001), cancer progression (P<0.0001), and cancer-specific death (P<0.0001).
|
25035170 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Additionally, after administration of TGF-β1 (increasing TGFBI level), the volume of tumor is obviously reduced in nude mice with injection of L02 cells stable expressing truncated HBsAg.
|
29609638 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Besides, the xenograft animal study showed that TGFBI knockout suppressed tumor growth and metastasis in vivo.
|
31598162 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
BXPC3 tumor xenografts demonstrated reduced growth with DDR1 knockdown, and the same xenograft tumors exhibited an increase in TGFBI expression level.
|
25369402 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
By contrast, the expanding control tumors showed intense TGFBI staining at the tumor edges, co-localizing with the fibrillar fibronectin/tenascin-C/periostin structures that characteristically surround melanoma cells at invasion fronts.
|
22326753 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, our findings demonstrate that TGFBIp is a lymphangiogenic factor contributing to tumor dissemination and represents a potential target to inhibit metastasis.
|
25772247 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, our results support the theory that TGFBI acts as a potent endogenous anti-tumor and anti-angiogenic molecule by targeting αvβ3 integrin, and highlights the importance of physiological circulating TGFBI levels in inhibiting tumor growth.
|
23792174 |
2013 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Dense methylation of the TGFBI promoter correlated with the extent of TGFBI gene silencing in tumor cell lines and was related to invasiveness of prostate tumors and metastatic status of lung cancer tumors.
|
18834524 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Epigenetic regulation of putative tumor suppressor TGFBI in human leukemias.
|
24791868 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Fibroblast growth factor signals regulate transforming growth factor-β-induced endothelial-to-myofibroblast transition of tumor endothelial cells via Elk1.
|
31094056 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, we found that targeting βig-h3 in established lesions released the tissue tension and functionally reprogrammed F4/80 macrophages in the tumour microenvironment.
|
30415234 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Identification and characterization of transforming growth factor beta-induced in circulating tumor cell subline from pancreatic cancer cell line.
|
30156359 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this study, ectopic expression of TGFBI was used to ascertain its role as a tumor suppressor and to determine the underlying mechanism of mesothelioma and breast cancer.
|
22695319 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It is known that βig-h3 is involved in the invasive process of many types of tumors, but its mechanism in glioma cells has not been fully clarified.
|
22629380 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It was found that the positive ratio of βig-h3 in the gastric cancer group was higher than that in the benign disease group, and the positive rate of immunohistochemistry was closely related to the relative factors of peritoneal metastasis such as tumor infiltration depth, serosal types, macroscopic peritoneal metastasis, CEA mRNA, results of pleural lavage cytology (PLC) examination, etc.
|
25864756 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MEK inhibition prevents tumour-shed transforming growth factor-β-induced T-regulatory cell augmentation in tumour milieu.
|
25284464 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Renal tissue from nine patients who had developed CyAN after successful heart or heart-lung transplantation and from four kidneys removed for tumour were analyzed for TGF-beta1 gene expression beta(ig)-H3 protein with reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry, respectively.
|
11740395 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, these data suggest that BIGH3 acts as a tumor suppressor in the retina.
|
28099942 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells.
|
16489022 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The findings provide strong evidence that the Betaig-h3 gene has tumour suppressor function in human BEP2D cell model and suggest a potential target for interventional therapy.
|
12085188 |
2002 |